Phase I/II study of SU11248 (Sutent) in combination with metronomic dosing of cyclophosphamide and methotrexate in patients with metastatic breast cancer

Trial Profile

Phase I/II study of SU11248 (Sutent) in combination with metronomic dosing of cyclophosphamide and methotrexate in patients with metastatic breast cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Dec 2013

At a glance

  • Drugs Sunitinib (Primary) ; Cyclophosphamide; Methotrexate
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Sep 2012 Planned end date changed from 1 Dec 2010 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 14 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top